CiiTECH Establishes CiiTECH Labs to Develop Breakthrough Cannabis Technology
A joint venture between cannabis CiiTECH and Hebrew University aims to treat fatty liver disease and obesity
JERUSALEM, May 26, 2020 (Newswire.com) - CiiTECH Labs announced today that it has developed and patented a breakthrough cannabis technology that has the potential to treat nonalcoholic fatty liver disease (NAFLD), obesity and other metabolic disorders. CiiTECH Labs is a newly established joint venture between CiiTECH a cannabis research and development company and Yissum, the tech transfer company of The Hebrew University of Jerusalem.
The cannabis technology is based on a recently completed study with the Hebrew University that demonstrated that a unique new cannabis formulation is able to influence the genes which play a key role in the metabolic process of fat absorption and its utilization as energy within the liver. The ability to influence the behavior of these molecular mechanisms has created what researchers believe could be a breakthrough technology in the fight against morbid obesity and fatty liver disease.
The study’s principal researcher and developer of the cannabis formulation, Hebrew University Prof. Yossi Tam, Head of Obesity and Metabolism at the Faculty of Medicine's School of Pharmacy, said, “Our recent findings have revealed the significant role that the endocannabinoid system (ECS) plays in the pathogenesis of NAFLD via the regulation of both CB1 and CB2 receptors. The results we achieved present compelling evidence that this specific combination of cannabinoids has the potential to treat NAFLD and its associated metabolic abnormalities”
According to the WHO, “Obesity is a global epidemic and mankind's biggest killer, claiming the lives of 15 million people every year with the average overweight rate in the Western world standing at 39% and climbing." Obesity costs national health services billions of pounds every year and “is believed to account for 80-85% of the risk of developing type 2 diabetes, while recent research suggests that obese people are up to 80 times more likely to develop type 2 diabetes than those with a BMI of less than 22,” according to diabetes.co.uk.
CiiTECH Founder & CEO, Clifton Flack said, “Metabolic research at CiiTECH Labs looks beyond diet and exercise to overcome the battle against obesity. Our team has discovered a unique ratio of specific cannabis compounds that together are able to influence the key genes that cause, or in our case, can now help prevent the pathway to obesity. We hope that if we can effectively treat obesity, we can be the first step in preventing the far more life-threatening metabolic conditions that obesity can cause.”
CiiTECH is a consumer brand cannabis company, invested in the research and development of non-psychoactive cannabis health products. Through this new joint venture with Hebrew University one of the visions is to discover and patent more formulations aimed at obesity and more serious metabolic conditions that are a result of obesity such as diabetes.
Media Inquiries Contact: email@example.com
Categories: Research and Development